[{"text": "BioVie Inc. ($BIVI) Joins Forces With New to The Street for a Dynamic 6-Part Media Campaign Featuring Long-Form Interviews, National TV Commercials, Iconic Billboards, and Exclusive Accredited Events New to The Street Mon, Jan 13, 2025, 5:00 PM 3 min read In This Article: BIVI -3.03% New to The Street, a leading FMW Media production, is thrilled to announce its partnership with BioVie Inc. (NASDAQ:BIVI), a clinical-stage biopharmaceutical company developing innovative therapies for neurodegenerative disorders and advanced liver disease. This partnership will launch a dynamic six-part media campaign designed to amplify BioVie's groundbreaking work to audiences across multiple platforms. The comprehensive campaign will include long-form biographical interviews aired on New to The Street's nationally syndicated TV networks, including Bloomberg and FOX Business Network. Additionally, the campaign features short-form TV commercials, iconic billboard placements in New York City and Las Vegas, and participation in exclusive AccreditedEvents.com investor roadshows, connecting BioVie with accredited investors and key stakeholders. \"We are excited to partner with BioVie Inc. and showcase their innovative approaches to tackling critical health challenges,\" said Vince Caruso, CEO and Managing Partner of New to The Street. \"This multi-platform campaign will leverage the full power of our media ecosystem-from television to outdoor advertising and investor events-to tell BioVie's story and support their mission of advancing patient care.\" As part of the campaign, BioVie's message will reach millions of homes across the U.S. and international markets, with additional exposure through New to The Street's 2.1 million YouTube subscribers and a combined 500,000+ followers on LinkedIn, Instagram, Facebook, and Twitter. Iconic outdoor placements, including the Nasdaq Tower and Reuters Building in Times Square, will amplify the impact of the campaign, offering unparalleled visibility in prime locations. About BioVie Inc. BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapies for neurological and neurodegenerative disorders, including Long COVID, Alzheimer's disease (AD), and Parkinson's disease (PD), as well as advanced liver disease. In neurodegenerative diseases, BioVie's lead candidate bezisterim targets the inflammatory activation of extracellular signal-regulated kinase (ERK) and nuclear factor-kB (NF-kB). By mitigating neuroinflammation and insulin resistance-key drivers of AD and PD-bezisterim addresses critical pathways without disrupting ERK and NF-kB's homeostatic roles, such as insulin signaling and neuronal growth. Additionally, bezisterim holds promise for alleviating persistent systemic and neuroinflammation in patients with neurological symptoms of Long COVID. Story Continues For advanced liver disease, BioVie is advancing BIV201 (continuous infusion terlipressin), an Orphan Drug with FDA Fast Track status. BIV201 is designed to reduce further decompensation in patients with liver cirrhosis and ascites. Its active agent, already approved in the U.S. and 40 other countries for related complications, is progressing toward Phase 3 clinical trials with FDA guidance. For more information, visit www.bioviepharma.com . About New to The Street New to The Street is an FMW Media production and one of the longest-running U.S. and international sponsored and syndicated Nielsen-rated television brands. Since 2009, the program has showcased biographical interview segment shows across major U.S. television networks, including Bloomberg and FOX Business Network, as sponsored programming. Its Nielsen-rated platform reaches millions of homes across the U.S. and international markets, making it a leader in broadcast media. With a growing audience of over 2.1 million YouTube subscribers and a combined 500,000+ followers across LinkedIn, Instagram, Facebook, and Twitter, New to The Street amplifies its reach beyond traditional TV. The platform further enhances its offerings through its partnership with AMI Accel Media International, providing access to iconic billboards in New York City and Las Vegas, including the Nasdaq Tower and Reuters Building in Times Square, as well as bus shelters in the Financial District. In addition, its short-form TV commercial division and collaboration with AccreditedEvents.com enable companies to reach accredited investors through exclusive non-deal roadshows, creating a unique, multi-platform media experience. For more information, visit www.newtothestreet.com . For Investor Relations Inquiries: Bruce Mackle Managing Director, LifeSci Advisors, LLC bmackle@lifesciadvisors.com For Media Relations Inquiries: Melyssa Weible Managing Partner, Elixir Health Public Relations mweible@elixirhealthpr.com New to The Street Monica Brennan Monica@newtothestreet.com Contact Information Monica Brennan Head of Operations monica@newtothestreet.com SOURCE: New to The Street View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BIVI", "date": "2025-01-13T14:00:00+00:00", "sentiment": {"score": 0.3617106843739748, "confidence": 0.3702353239059448, "probabilities": {"positive": 0.3702353239059448, "negative": 0.008524639531970024, "neutral": 0.6212400197982788}}, "embedding": [-0.02052663080394268, -0.22688668966293335, 0.0007031690329313278, -0.1124398410320282, 0.022870108485221863, 0.02591157890856266, -0.13782759010791779, 0.10063669085502625, 0.15210463106632233, -0.027609406039118767, -0.1411103904247284, 0.0926925539970398, 0.01565699651837349, 0.08536514639854431, 0.037743933498859406, -0.07953666150569916, 0.07668252289295197, -0.02196539379656315, -0.03783474862575531, 0.12425024807453156, 0.042860597372055054, 0.03715350478887558, 0.08158139884471893, 0.031426120549440384, -0.04926203936338425, 0.056318096816539764, -0.05715981498360634, 0.032970916479825974, -0.07683578133583069, -0.008484169840812683, 0.12154537439346313, 0.1676197648048401, 0.12406674027442932, -0.10528199374675751, -0.02019774541258812, -0.03015090525150299, -0.09556633234024048, 0.0365266315639019, -0.07853245735168457, -0.017678894102573395, 0.01549891009926796, -0.08748222142457962, -0.08009326457977295, -0.04535895586013794, 0.1382807195186615, -0.24173055589199066, -0.0275727491825819, 0.11557179689407349, 0.1605921983718872, 0.04412646219134331, -0.2304157316684723, -0.13712546229362488, 0.09881985187530518, 0.03215981274843216, 0.042310431599617004, -0.008023420348763466, -0.09579260647296906, -0.08534475415945053, 0.05733850598335266, 0.005584062542766333, 0.12747925519943237, -0.03935707360506058, 0.04074595123529434, 0.07895125448703766, 0.16400761902332306, -0.04835379496216774, 0.029961183667182922, 0.15543514490127563, -0.014376209117472172, -0.10415035486221313, 0.053142108023166656, -0.09769836068153381, 0.025762617588043213, 0.08566290140151978, 5.214993143454194e-05, 0.22661671042442322, 0.09277549386024475, -0.006791530642658472, 0.08252014219760895, -0.17263707518577576, 0.08658798038959503, -0.15488821268081665, -0.023867985233664513, 0.033012427389621735, 0.012089657597243786, -0.0050676376558840275, 0.014307226985692978, 0.05467119440436363, -0.07477807253599167, 0.03397044166922569, -0.24696987867355347, -0.0006419327110052109, 0.11497490108013153, -0.04563865438103676, -0.027614939957857132, -0.03339028358459473, -0.08768295496702194, -0.09331974387168884, 0.16350191831588745, 0.03826066106557846, -0.052345551550388336, 0.02472129836678505, -0.02281169965863228, -0.029036158695816994, -0.00903183501213789, -0.14890801906585693, 0.03473685309290886, 0.16413646936416626, 0.06600305438041687, 0.1311209797859192, -0.06164459511637688, 0.16483427584171295, -0.010702744126319885, -0.062360815703868866, -0.07722983509302139, 0.2163509875535965, -0.08609695732593536, -0.0102546326816082, 0.12031184881925583, 0.04262261092662811, 0.0019251927733421326, 0.13166382908821106, -0.07935675978660583, -0.09821344912052155, 0.11432206630706787, -0.07613463699817657, -0.10239380598068237, 4.750102509353799e-33, -0.05166131630539894, 0.10235190391540527, 0.052558429539203644, 0.058722689747810364, -0.03450896590948105, 0.15050730109214783, -0.07358798384666443, 0.0071158516220748425, -0.1300646960735321, -0.09220459312200546, -0.04284451901912689, 0.1493629813194275, 0.020506635308265686, 0.21623998880386353, -0.13100971281528473, -0.10772278904914856, -0.13147369027137756, -0.0688433051109314, -0.003069675527513027, -0.05448291450738907, -0.026584748178720474, -0.01328863762319088, -0.06689590215682983, 0.15470953285694122, 0.00021176226437091827, -0.0660087913274765, -0.04848087579011917, 0.1146894246339798, 0.045580778270959854, 0.0444922149181366, -0.11537986993789673, 0.01611023023724556, 0.03512992709875107, -0.17753317952156067, 0.007572659291327, -0.14072692394256592, -0.11242185533046722, -0.1875438094139099, -0.11032219976186752, 0.16822156310081482, -0.027883542701601982, 0.036956001073122025, -0.22663810849189758, 0.013170678168535233, -0.05659418925642967, 0.1539963185787201, -0.003427563700824976, 0.0025326088070869446, -0.020346907898783684, 0.15973445773124695, 0.0014284034259617329, 0.025752123445272446, -0.14883089065551758, -0.15473522245883942, -0.03011014498770237, 0.03141739219427109, -0.10223200917243958, -0.21717610955238342, 0.04333747923374176, -0.010416851378977299, 0.04322459176182747, 0.18836760520935059, -0.037244200706481934, 0.0983256846666336, -0.1500145047903061, 0.11320604383945465, 0.16781854629516602, 0.059176526963710785, -0.036209337413311005, 0.09521128237247467, -0.009144923649728298, 0.0405653715133667, 0.06679747253656387, -0.05946579948067665, 0.04622619226574898, -0.016202112659811974, -0.12599612772464752, -0.07810546457767487, -0.001976592931896448, 0.06453559547662735, 0.04610755294561386, 0.006098998710513115, 0.09991127252578735, 0.10718194395303726, 0.11506336182355881, 0.022093117237091064, -0.04325509071350098, -0.048411495983600616, -0.0979706197977066, -0.09009881317615509, 0.025349505245685577, -0.037096306681632996, -0.10655158013105392, 0.19042356312274933, 0.021537067368626595, -6.805166018308633e-33, -0.10698704421520233, -0.04307384043931961, 0.06247048079967499, -0.05255501717329025, -0.009389316663146019, -0.02614256739616394, -0.035396963357925415, -0.1276686191558838, 0.13193364441394806, -0.03379060700535774, -0.022505033761262894, -0.043214455246925354, -0.07158768177032471, 0.043202951550483704, -0.0910363718867302, -0.006263454910367727, 0.04369451850652695, -0.19463473558425903, -0.08891721069812775, 0.1180533766746521, 0.0674535483121872, 0.12413876503705978, -0.1261122226715088, 0.06805159896612167, 0.006938008591532707, 0.06758737564086914, 0.1599036455154419, 0.04323847219347954, 0.11200767010450363, -0.004040237981826067, -0.050943199545145035, 0.022074280306696892, -0.22108887135982513, -0.007420243229717016, 0.037805262953042984, 0.19591757655143738, 0.061298444867134094, -0.206903874874115, -0.08971334993839264, -0.14522139728069305, 0.08684170246124268, 0.002108937129378319, -0.10911321640014648, -0.05856127291917801, -0.08174492418766022, -0.01892140507698059, 0.05102154612541199, 0.011336113326251507, 0.04688647389411926, 0.1024128869175911, -0.0036819176748394966, 0.10534588247537613, 0.02543499693274498, 0.04500821232795715, -0.039096374064683914, -0.10494501143693924, -0.01982560195028782, 0.1549607515335083, 0.06296481937170029, 0.03917326033115387, 0.08317011594772339, 0.007372425869107246, -0.048736803233623505, -0.08072400093078613, 0.021872928366065025, -0.005376785062253475, 0.13123497366905212, 0.056310053914785385, -0.06741199642419815, -0.024239052087068558, -0.00804496556520462, -0.029523150995373726, -0.008902207016944885, -0.1516491174697876, -0.1441836953163147, 0.09574019908905029, -0.04902036115527153, -0.1122613400220871, -0.12518146634101868, -0.03500812500715256, 0.0591932013630867, -0.059719018638134, 0.07868397980928421, 0.06754159927368164, 0.14110732078552246, 0.11572866141796112, -0.08401419222354889, -0.008668174967169762, -0.08965054154396057, 0.09835606813430786, 0.01205207034945488, -0.03315373510122299, -0.14699634909629822, 0.010816539637744427, -0.06541016697883606, -1.0089850377426046e-07, 0.028786204755306244, -0.046754367649555206, -0.050973452627658844, -0.05667953938245773, 0.10183808207511902, -0.08737991750240326, -0.06398962438106537, 0.05154646188020706, 0.12621676921844482, 0.20737484097480774, 0.11499452590942383, 0.08044067025184631, -0.14390254020690918, 0.032789163291454315, -0.05471467971801758, 0.016117427498102188, -0.14300045371055603, 0.011385733261704445, -0.03603937104344368, -0.041324228048324585, -0.19100616872310638, 0.0513601116836071, -0.025723224505782127, -0.06986024230718613, 0.05819612368941307, -0.16796736419200897, 0.032864559441804886, -0.0720072090625763, 0.13916030526161194, -0.11903776228427887, -0.025504712015390396, 0.026039786636829376, -0.10556979477405548, -0.025757018476724625, -0.046719059348106384, -0.21200209856033325, 0.10130129754543304, 0.07333605736494064, 0.04277338832616806, 0.130708247423172, 0.08534448593854904, -0.04226396977901459, -0.027548491954803467, -0.019022133201360703, 0.003834029659628868, 0.029333988204598427, -0.03576861694455147, 0.047897834330797195, 0.10819214582443237, -0.17095355689525604, -0.059595778584480286, -0.09306074678897858, 0.05250569060444832, -0.0005071409977972507, 0.017882999032735825, 0.10887023061513901, -0.04765450581908226, -0.031553465873003006, 0.05538926273584366, 0.07878820598125458, 0.06440213322639465, -0.10343880951404572, 0.09994564205408096, 0.020133022218942642], "changes": {"1wk": 6.666671964857554}}, {"text": "BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference BioVie, Inc. Wed, Nov 20, 2024, 4:00 PM 5 min read In This Article: BIVI -3.03% BioVie, Inc. CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (\u201cBioVie\u201d or the \u201cCompany\u201d), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an\u00a0abstract on the design of its planned Phase 2 trial evaluating bezisterim in Long COVID has been accepted as a poster presentation at the Demystifying Long COVID International Conference, November 21 st & 22 nd 2024, in Barcelona Spain. The planned Phase 2 study, which is fully funded by a grant from the U.S. Department of Defense (DOD), is a double-blind, randomized (1:1), placebo-controlled, multicenter trial in approximately 200 patients to evaluate the safety, tolerability and potential efficacy of 3 months of treatment with bezisterim to reduce the neurocognitive symptoms associated with Long COVID. Details for the presentation are as follows: Title : A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults with Long COVID Poster number : 28 Presentation date : November 21, 2024 Presenter : Penelope Markham, Ph.D, Senior Vice President and Program Lead, Long COVID, BioVie Inc. About Long COVID Long COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or more. Common symptoms include lingering loss of smell and taste, extreme fatigue, and \u201cbrain fog,\u201d though persistent cardiovascular and respiratory problems, muscle weakness, and neurologic issues have also been documented. The Centers for Disease Control recently reported that 6.8% of adults in the United States (more than 17 million individuals) currently or previously have long COVID 1 though a recent analysis using real world data estimates the prevalence could be as high as 22% 2 . The loss in quality of life and earnings and increased medical costs has an enormous economic impact estimated to be $3.7 trillion 3 . To date there are no non-pharmacological or pharmacological therapies proven effective for treatment of long COVID. Terms of the Department of Defense Award The work is supported by the Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, by a fully funded award in the amount of $13,137,150 through the Peer Reviewed Medical Research Program (PRMRP) under Award No. HT9425-24-1-0113. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs or the Department of Defense. Story Continues About BioVie Inc. BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Long COVID, Alzheimer's disease and Parkinson\u2019s disease) and advanced liver disease. In neurodegenerative disease, the Company\u2019s drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance but not ERK and NFkB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD.\u00a0Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of Long COVID. In liver disease, the Company\u2019s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com . References 1 Ford ND, Agedew A, Dalton AF, Singleton J, Perrine CG, Saydah S. Notes from the Field: Long COVID Prevalence Among Adults \u2014 United States, 2022. MMWR Morb Mortal Wkly Rep 2024;73:135\u2013136. DOI: http://dx.doi.org/10.15585/mmwr.mm7306a4 . 2 Azhir A et al. \u201cPrecision Phenotyping for Curating Research Cohorts of Patients with Unexplained Post-Acute Sequelae of COVID-19\u201d Med DOI: 10.1016/j.medj.2024.10.009, in press 3 Cutler, David M. 2022 The economic costs of Long COVID: An update. long_covid_update_7-22.pdf (harvard.edu) Forward-Looking Statements This press release contains forward-looking statements, which may be identified by words such as \"expect,\" \"look forward to,\" \"anticipate\" \"intend,\" \"plan,\" \"believe,\" \"seek,\" \"estimate,\" \"will,\" \"project\" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. For Investor Relations Inquiries: Bruce Mackle Managing Director, LifeSci Advisors, LLC bmackle@lifesciadvisors.com For Media Relations Inquiries: Melyssa Weible Managing Partner, Elixir Health Public Relations mweible@elixirhealthpr.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "BIVI", "date": "2024-11-20T13:00:00+00:00", "sentiment": {"score": -0.0005964450538158417, "confidence": 0.05718184635043144, "probabilities": {"positive": 0.0565854012966156, "negative": 0.05718184635043144, "neutral": 0.8862327933311462}}, "embedding": [-0.04277956113219261, -0.06402144581079483, -0.015847036615014076, 0.03410981222987175, -0.024460092186927795, 0.02009223774075508, -0.17206361889839172, 0.23260846734046936, -0.009006716310977936, 0.13786259293556213, -0.06454519182443619, 0.09638575464487076, 0.011903354898095131, 0.1230873167514801, -0.07632903754711151, 0.0024110139347612858, 0.060207679867744446, -0.054991066455841064, 0.012986313551664352, 0.048635438084602356, 0.05768836289644241, -0.015249287709593773, 0.09718652814626694, 0.016459720209240913, -0.0902625024318695, 0.08224447071552277, -0.14727240800857544, -0.05114082992076874, -0.06321656703948975, 0.022242149338126183, 0.12683305144309998, 0.16651651263237, -0.022862274199724197, -0.041911981999874115, -0.10506529361009598, 0.01715771295130253, -0.03839094191789627, 0.05797199159860611, -0.16628506779670715, 0.0006680767983198166, -0.08530505001544952, 0.03999171778559685, 0.029884779825806618, 0.00934064295142889, 0.02166939713060856, -0.15673072636127472, -0.15918812155723572, 0.05492120236158371, 0.01144337933510542, 0.1057208776473999, -0.08895960450172424, -0.062316589057445526, 0.05270543694496155, 0.12100175023078918, 0.04057972505688667, 0.006016426719725132, -0.15866661071777344, -0.11312979459762573, -0.06615766882896423, 0.10285933315753937, -0.05729129537940025, 0.0333528034389019, -0.030353475362062454, -0.05079410970211029, 0.08449618518352509, 0.048664070665836334, 0.019349727779626846, -0.06719622761011124, 0.07666532695293427, 0.007370594888925552, 0.0475868284702301, -0.1238364577293396, -0.059919409453868866, 0.050592634826898575, -0.07307974994182587, 0.048743486404418945, 0.15846845507621765, -0.033563628792762756, 0.12208421528339386, -0.16140609979629517, 0.050775907933712006, 0.11443240940570831, 0.15225215256214142, -0.03666739538311958, 0.06867725402116776, 0.007753080688416958, -0.10658258199691772, 0.162107914686203, -0.0694824680685997, 0.05020914599299431, 0.1286238133907318, -0.01523305382579565, -0.009509189054369926, 0.03785625100135803, 0.05412488430738449, 0.005286051891744137, 0.02163742482662201, 0.05120153725147247, -0.013910233974456787, -0.01635054312646389, 0.025326993316411972, -0.10540571063756943, -0.043659508228302, -0.0718059167265892, -0.023052694275975227, -0.037927497178316116, 0.17538398504257202, -0.0019443109631538391, 0.052649982273578644, -0.01986902952194214, -0.053229182958602905, 0.1138913631439209, -0.0014006756246089935, 0.02030421420931816, -0.036112815141677856, 0.2546500563621521, -0.03627774864435196, 0.04238313436508179, 0.1300211101770401, 0.036850254982709885, 0.09046753495931625, -0.04420190304517746, 0.06673916429281235, -0.13551101088523865, 0.12336064875125885, 0.03860724717378616, -0.04062286764383316, 7.243388108243274e-33, -0.020083000883460045, 0.06067517027258873, -0.016713054850697517, 0.12418058514595032, -0.07131237536668777, 0.0526784211397171, 0.09660710394382477, 0.1804693043231964, -0.05712436884641647, -0.025091953575611115, 0.002329610288143158, -0.007448574528098106, 0.006206489633768797, 0.19891095161437988, -0.0688173696398735, -0.018667295575141907, -0.06426607072353363, 0.067721426486969, -0.10727843642234802, 0.03113928809762001, 0.10058297216892242, 0.029271898791193962, 0.058281704783439636, 0.08037006855010986, 0.07824084162712097, -0.07578017562627792, -0.1348758339881897, 0.13618484139442444, 0.03531191498041153, 0.035346705466508865, -0.028745971620082855, 0.040093012154102325, -0.06058531999588013, -0.05359025299549103, -0.16894710063934326, -0.13289014995098114, -0.043466076254844666, -0.033934585750103, -0.10625742375850677, 0.07648132741451263, 0.033445652574300766, 0.12547287344932556, -0.07679835706949234, -0.006459793075919151, 0.07284709066152573, -0.1341986358165741, -0.019882284104824066, -0.045774590224027634, -0.09597774595022202, 0.029048394411802292, -0.0017718970775604248, 0.0764751136302948, -0.10965321958065033, -0.07370322942733765, -0.08194000273942947, 0.09227488934993744, -0.02281070128083229, 0.0024444670416414738, 0.1269194781780243, 0.030763529241085052, 0.044392429292201996, 0.11069604754447937, -0.07121782004833221, 0.023443592712283134, -0.009125085547566414, -0.0731397196650505, 0.02247648313641548, -0.09077762812376022, -0.05323129519820213, -0.007554635871201754, 0.006696166470646858, -0.09562335908412933, 0.09178417176008224, 0.0343775637447834, 0.023962074890732765, -0.10170897841453552, -0.005917288828641176, 0.0827840268611908, -0.04974840208888054, -0.16865991055965424, -0.05060043931007385, 0.061460986733436584, 0.017786594107747078, 0.12931112945079803, 0.015610862523317337, 0.0852336585521698, -0.012378863990306854, -0.07756748795509338, -0.1839180290699005, -0.10950572788715363, 0.09870584309101105, 0.04414178058505058, 0.0289115309715271, -0.01974445953965187, 0.06286206096410751, -8.564834776399534e-33, -0.10656842589378357, 0.019167020916938782, -0.08192522078752518, -0.04718221724033356, 0.018731646239757538, 0.14187537133693695, 0.12395279109477997, -0.06776128709316254, 0.07500959187746048, -0.2962932586669922, 0.07209747284650803, 0.028839584439992905, 0.017244432121515274, 0.0121603449806571, -0.00687028793618083, 0.03700410947203636, -0.07285082340240479, -0.020792214199900627, -0.06684665381908417, 0.003616154659539461, 0.10778973996639252, 0.10273757576942444, -0.11842633783817291, -0.0304911769926548, -0.01069475058466196, 0.027500048279762268, 0.0993456244468689, -0.06905996799468994, 0.051969390362501144, 0.03228525444865227, -0.012559333816170692, 0.02194741927087307, -0.2303517609834671, 0.030780162662267685, 0.0840834230184555, -0.037231527268886566, -0.0002905186265707016, -0.16747573018074036, -0.16282746195793152, -0.11454910039901733, 0.0880146473646164, 0.11840350925922394, -0.021820776164531708, -0.026377452537417412, 0.0872831642627716, 0.036037784069776535, 0.026093773543834686, -0.07616695761680603, 0.1263113170862198, 0.05668715015053749, -0.07953045517206192, -0.05291027948260307, -0.08905656635761261, 0.01813385635614395, 0.023934656754136086, -0.1872575283050537, -0.09128622710704803, -0.06098603457212448, -0.059668950736522675, 0.012355269864201546, 0.0017719478346407413, 0.1065501868724823, -0.1091693788766861, -0.12091975659132004, 0.2109394371509552, 0.0893683135509491, 0.028980791568756104, 0.07374972850084305, 0.14715540409088135, -0.0779324471950531, -0.13674604892730713, -0.11825451254844666, -0.1119796484708786, -0.07692348212003708, -0.03967652469873428, 0.05530519410967827, 0.017741307616233826, -0.053031887859106064, -0.08110301196575165, -0.028363237157464027, -0.010982869192957878, -0.13627822697162628, 0.011843119747936726, 0.005729456897825003, 0.023372307419776917, -0.027914445847272873, 0.01407628133893013, -0.0519036166369915, 0.021929919719696045, 0.05159085616469383, -0.07910627871751785, -0.06318399310112, -0.12456837296485901, -0.05623246729373932, -0.04247511923313141, -1.0030277763917184e-07, 0.14140355587005615, -0.048765912652015686, 0.05910670384764671, 0.03259371221065521, 0.02314518392086029, 0.029510926455259323, -0.08628906309604645, -0.00819767639040947, -0.08693411946296692, 0.20389704406261444, 0.09533404558897018, 0.08447222411632538, 0.012328527867794037, -0.024641109630465508, -0.09637267142534256, 0.009013514034450054, -0.07882294803857803, 0.1105492115020752, -0.10026147216558456, -0.05569656193256378, -0.1045532375574112, -0.06362402439117432, -0.05086226761341095, -0.07978136092424393, -0.04431656748056412, -0.027459383010864258, 0.058687515556812286, 0.00917793344706297, 0.06984427571296692, -0.16173523664474487, -0.15322592854499817, 0.03512074053287506, 0.055913519114255905, 0.0541280061006546, 0.03397444635629654, -0.19069604575634003, 0.14319726824760437, 0.14269563555717468, 0.1283290684223175, 0.1414741575717926, 0.09979867190122604, 0.013080630451440811, -0.0030620694160461426, 0.05705372244119644, 0.09590352326631546, -0.08037395030260086, -0.06053255498409271, -0.07172764837741852, 0.013995703309774399, -0.05990298092365265, -0.024415522813796997, 0.032478369772434235, 0.02872561663389206, -0.01259056106209755, -0.006806175224483013, 0.17505469918251038, -0.08334552496671677, -0.031206831336021423, 0.0012772922636941075, -0.15435324609279633, 0.11293858289718628, -0.045938361436128616, -0.05396563559770584, 0.04583846032619476], "changes": {"1wk": -16.07142793787578, "1mo": -38.09523843313292}}]